Medline (NASDAQ:MDLN) Coverage Initiated by Analysts at Bank of America

Bank of America assumed coverage on shares of Medline (NASDAQ:MDLN) in a research report issued on Monday. The brokerage set a “buy” rating and a $50.00 price target on the stock. Bank of America‘s target price points to a potential upside of 18.48% from the company’s previous close.

A number of other research analysts have also recently weighed in on MDLN. William Blair began coverage on Medline in a research report on Monday. They issued an “outperform” rating for the company. Sanford C. Bernstein initiated coverage on Medline in a research report on Monday. They set an “outperform” rating and a $49.00 target price on the stock. Evercore ISI started coverage on Medline in a report on Monday. They issued an “outperform” rating and a $50.00 price target for the company. Robert W. Baird started coverage on shares of Medline in a report on Monday. They set an “outperform” rating and a $48.00 price objective on the stock. Finally, The Goldman Sachs Group started coverage on shares of Medline in a report on Monday. They issued a “buy” rating and a $49.00 target price for the company. Twenty-three equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $46.70.

Medline Trading Up 4.1%

Shares of MDLN stock traded up $1.68 during midday trading on Monday, reaching $42.20. 1,360,689 shares of the company traded hands, compared to its average volume of 5,609,583. Medline has a 1-year low of $34.89 and a 1-year high of $45.50.

Insider Activity at Medline

In related news, Director Charles N. Mills bought 2,579,310 shares of the stock in a transaction dated Thursday, December 18th. The stock was acquired at an average price of $29.00 per share, for a total transaction of $74,799,990.00. Following the completion of the purchase, the director owned 2,441,379 shares in the company, valued at $70,799,991. This represents a -1,870.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Andrew J. Mills purchased 2,586,206 shares of Medline stock in a transaction that occurred on Thursday, December 18th. The shares were bought at an average cost of $29.00 per share, for a total transaction of $74,999,974.00. Following the completion of the transaction, the director directly owned 2,586,206 shares in the company, valued at $74,999,974. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

Key Headlines Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Jefferies initiated coverage with a Buy and $50 target, highlighting Medline’s scale (a cited $25B supply‑chain advantage) as a key driver for margin and growth upside. Read More.
• Positive Sentiment: Barclays started coverage Overweight with a $50 target, joining other major shops that see meaningful upside tied to Medline’s distribution scale. Read More.
• Positive Sentiment: Wolfe Research (Outperform, $47), Mizuho (Outperform, $48) and JPMorgan (Overweight, $50) all initiated positive ratings, reinforcing a consensus bullish view on share gains from market share and margin expansion. Read More. Read More.
• Positive Sentiment: Multiple boutique and sector analysts (Bernstein, Baird, Piper Sandler, Truist, Stifel, William Blair, Leerink and others) also initiated Buy/Overweight calls, citing the “prime‑vendor” model, branded mix shift and visible margin runway; see a TipRanks roundup of these initiations. Read More.
• Positive Sentiment: Positive media/TV coverage (including Jim Cramer commentary) has added to the bullish tone, amplifying retail and institutional interest. Read More.
• Neutral Sentiment: Wells Fargo initiated with an Equal Weight and $42 target, and Rothschild/Redburn started Neutral at $42 — signaling some caution on near‑term upside despite the broader buy consensus. Read More.
• Negative Sentiment: Deutsche Bank started with a Hold and $40 target (slight downside vs. current levels), representing the most cautious early call and a reminder of valuation risk if execution or margins disappoint. Read More.

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.